Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-21
2005-06-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233200, C514S243000, C514S228500, C540S492000, C540S575000, C544S061000, C544S062000, C544S112000, C544S183000
Reexamination Certificate
active
06908916
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 4908056 (1990-03-01), Tseng
patent: 778 277 (1997-06-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 01/14378 (2001-01-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Traxler, Protein Tyrosine Kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6):571-588, 1997.
Marmor et al., Signal Transduction and Oncogenesis by ErbB/HER Receptors, Int. J. Radiation Oncology Biol. Phys., vol. 58, No. 3, pp. 903-913, 2004.
Otter et al, Nucleoside & Nucleotides, 15(1-3), 793-807 (1996).
Quintela et al, Tetrahedron, 52(8), 3037-3048 (1996).
Patil et al, J. Heterocyclic Chem., 31(4), 781-807 (1994).
Neunhoeffer et al, Justus Liebigs Ann. Chem., vol. 9, 1413-1420 (1977) & Chem. Abstr. 88:121113q, (Apr. 1978).
Skobe et al, Nature Medicine, vol. 3, No. 11, 1223-1227 (Nov. 1997).
Mastalerz Harold
Tarrant James G.
Vite Gregory D.
Zhang Guifen
Bristol Myers Squibb Company
Korsen Elliott
Peist Kenneth
Rao Deepak
LandOfFree
C-5 modified indazolylpyrrolotriazines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-5 modified indazolylpyrrolotriazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-5 modified indazolylpyrrolotriazines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3466086